Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antisynthetase syndrome.

Agathe Imbert-Masseau1, Mohamed Hamidou, Christian Agard

  • 1Internal Medicine Department A, Hôtel-Dieu, Nantes Teaching Hospital, 1 place Alexis Ricordeau, 44093, Nantes, France. agathe.masseau@caramail.com

Joint Bone Spine
|June 20, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Occupational category, job type, and sarcoidosis: Findings from a French multicenter study.

Pulmonology·2026
Same author

Aortitis accelerates the growth rate of thoracic aortic aneurysms.

RMD open·2026
Same author

French recommendations for the use of imaging in giant cell arteritis.

Joint bone spine·2026
Same author

Lingual Raynaud's Phenomenon: A Case Series and Literature Review.

Journal of clinical medicine·2026
Same author

Antineutrophil Cytoplasmic Antibody-Associated Vasculitides in Systemic Sclerosis: A Unique Clinical Overlap With Significant Implications for Treatment and Outcomes.

Arthritis & rheumatology (Hoboken, N.J.)·2025
Same author

Polyarteritis nodosa associated with VEXAS syndrome and chronic myelomonocytic leukemia: a case-control study.

Rheumatology (Oxford, England)·2025
Same journal

Greater trochanteric bursal distension with intra-bursal rice bodies: an unusual MRI presentation.

Joint bone spine·2026
Same journal

Evaluating the Impact of a Rheumatologist-led Comorbidity Review in Patients with Inflammatory Arthritis.

Joint bone spine·2026
Same journal

What cumulative glucocorticoid dose should trigger sparing strategies in polymyalgia rheumatica?

Joint bone spine·2026
Same journal

Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update.

Joint bone spine·2026
Same journal

Multimodal imaging evaluation of the entheses in spondyloarthritis.

Joint bone spine·2026
Same journal

Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update. What's new?

Joint bone spine·2026
See all related articles

Antisynthetase syndrome involves autoantibodies targeting synthetases, causing interstitial lung disease (ILD) and muscle inflammation. This condition significantly impacts prognosis, with unknown causes and varied treatment responses.

Area of Science:

  • Rheumatology
  • Immunology
  • Pulmonology

Background:

  • Antisynthetase syndrome is an autoimmune disorder characterized by autoantibodies against synthetase enzymes.
  • Synthetases are crucial for protein synthesis, specifically tRNA acetylation.
  • The anti-Jo1 autoantibody is the most common marker associated with this syndrome.

Purpose of the Study:

  • To summarize the key features of antisynthetase syndrome.
  • To highlight the clinical manifestations, particularly interstitial lung disease (ILD).
  • To discuss the prognostic implications and current understanding of pathogenic mechanisms and treatment.

Main Methods:

  • Literature review and synthesis of existing data on antisynthetase syndrome.
  • Analysis of clinical characteristics, including autoantibody profiles, organ involvement, and patient outcomes.

Related Experiment Videos

  • Review of proposed pathogenic mechanisms and therapeutic strategies.

    • Main Results:

    • Antisynthetase syndrome commonly presents with anti-Jo1 antibodies, interstitial lung disease (ILD), and inflammatory myopathy.
    • Associated symptoms include fever, arthritis, Raynaud's phenomenon, and mechanic's hands.
    • The ILD, often usual interstitial pneumopathy, is a major determinant of prognosis, with a 40% mortality rate.

    Conclusions:

    • The pathogenesis of antisynthetase syndrome is not fully understood but may involve cell-mediated immunity.
    • Treatment is not standardized, with variable responses to glucocorticoids and other immunosuppressants.
    • Further research is needed to elucidate mechanisms and optimize treatment for this severe autoimmune condition.